Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

Abstract Most patients with relapsed or metastatic head and neck squamous cell carcinoma (rmHNSCC) do not experience durable responses to PD-1 immune checkpoint inhibitors. PD-L1 tissue expression is the most commonly assessed response marker, but an insufficient predictor of treatment outcome. To i...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisa Paschold, Christoph Schultheiss, Paul Schmidt-Barbo, Konrad Klinghammer, Dennis Hahn, Mareike Tometten, Philippe Schafhausen, Markus Blaurock, Anna Brandt, Ingunn Westgaard, Simone Kowoll, Alexander Stein, Axel Hinke, Mascha Binder
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-01020-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-025-01020-6

Similar Items